Episode Details
Back to Episodes
Pareto Securities Healthcare Conference: BioInvent believes that it has found the next big checkpoint in TNFR2 - this summer they had data both in solid and liquid tumors
Published 1 week, 6 days ago
Description
CEO Martin Welschof walks us through recent ASCO (ovarian in combo with Keytruda) and EHA (CTLC) data for BI-1808, and describes why the company believes TNFR2 is a compelling checkpoint with wide applicability. Plus, BI-1206 (FcyRIIB), which will have NCSLC data later this year and BioInvent ultimately hopes to partner.